Biogen's fair value estimate has nudged higher to about $178.76 per share, even as its discount rate ticks up slightly to roughly 7.49 %, signaling a modestly higher perceived risk backdrop. The shift ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback